Flibanserin (hydrochloride)

Flibanserin hydrochloride (BIMT-17 hydrochloride) is an orally active 5-HT1A receptor agonist and 5-HT2A receptor antagonist with binding affinities Ki of 1 nM and 49 nM, respectively. Flibanserin hydrochloride also binds to dopamine D4 receptors with a Ki of 4-24 nM. Flibanserin hydrochloride has antidepressant and anxiolytic effects and can be used in the study of hypoactive sexual desire disorder (HSDD) [1].

Product Specifications

CAS Number

[147359-76-0]

Product Name Alternative

BIMT-17 (hydrochloride) ; BIMT-17BS (hydrochloride)

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

O=C1NC2=C(N1CCN3CCN(CC3)C4=CC=CC(C(F)(F)F)=C4)C=CC=C2.Cl

Molecular Formula

C20H22ClF3N4O

Molecular Weight

426.86

References & Citations

[1]El-Behairy, et al. "Insights into flibanserin oxidative stress degradation pathway: in silico–in vitro toxicity assessment of its degradates." New Journal of Chemistry 45.5 (2021) : 2620-2630.|[2]Invernizzi, Roberto William, et al. "Flibanserin, a potential antidepressant drug, lowers 5‐HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5‐HT1A receptors." British journal of pharmacology 139.7 (2003) : 1281-1288.|[3]Gelez, et al. "Brain neuronal activation induced by flibanserin treatment in female rats." Psychopharmacology 230 (2013) : 639-652.|[4]Podhorna, et al. "Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety." British journal of pharmacology 130.4 (2000) : 739-746.|[5]Gelman, et al. "Flibanserin for hypoactive sexual desire disorder: place in therapy." Therapeutic Advances in Chronic Disease 8.1 (2017) : 16-25.